Tumor Lysis Syndrome clinical trials
The registry lists 20 studies for Tumor Lysis Syndrome across 7 countries. 1 are recruiting or about to start. 7 of them are mainly about Tumor Lysis Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-07-31.
Get an email when these change. Save the Tumor Lysis Syndrome studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Celgene (4) · Sanofi (4) · M.D. Anderson Cancer Center (4) · Menarini Group (2) · National Cancer Institute (NCI) (1) · Lomond Therapeutics Holdings, Inc. (1) · University Hospital, Geneva (1) · AstraZeneca (1)
What is being tested here
Drugs under test in Tumor Lysis Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Rasburicase | 0 | 1 | 5 |
| Allopurinol | 0 | 1 | 2 |
| Febuxostat | 0 | 1 | 2 |
| Pegloticase | 0 | 0 | 1 |
| Venetoclax | 0 | 1 | 1 |
| Alvocidib | 0 | 0 | 1 |
| AZD0466 | 0 | 0 | 1 |
Who these studies take
Of the 1 Tumor Lysis Syndrome studies recruiting now, 1 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 1 (100%) | 1 (100%) |
| 30 | 1 (100%) | 1 (100%) |
| 40 | 1 (100%) | 1 (100%) |
| 50 | 1 (100%) | 1 (100%) |
| 65 | 1 (100%) | 1 (100%) |
| 75 | 1 (100%) | 1 (100%) |
| 85 | 1 (100%) | 1 (100%) |
Across all 20 studies, recruiting or not: 0% stop at 75 or younger and 0% at 65; 35% take children; 0% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 20 of 20. search them.
- A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell MalignanciesRecruitingNCT06708897Phase 11 country
- Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis SyndromeCompletedNCT04745910Phase 41 country
- Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)CompletedNCT030985891 country
- A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination TherapyCompletedNCT03406156Phase 31 country
- A Study of AZD0466 in Patients With Advanced Hematologic or Solid TumorsTerminatedNCT04214093Phase 11 country
- A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-LymphomaActive, not recruitingNCT058402891 country
- A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mgCompletedNCT029218282 countries
- A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of UseCompletedNCT029225431 country
- A Study of Special Use Results Surveillance of Revlimid 5mg CapsulesCompletedNCT029218021 country
- Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and AdultsTerminatedNCT03605212Phase 1/24 countries
- Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2CompletedNCT01200485Phase 21 country
- Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell LymphomaCompletedNCT00445341Phase 1/21 country
- Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy PatientsCompletedNCT001869401 country
- Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic MalignanciesCompletedNCT01724528Phase 3
- Rasburicase in Patients at Risk for Tumor Lysis SyndromeCompletedNCT00628628Phase 21 country
- Elitek (Rasburicase) Immuno-Monitoring StudyTerminatedNCT010973691 country
- Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLSCompletedNCT00360438Phase 1/21 country
- Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis SyndromeCompletedNCT00230178Phase 31 country
- Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor MalignancyCompletedNCT00230217Phase 41 country
- Fasturtec TLS Treatment / ProphylysisCompletedNCT00651911Phase 41 country